MA
MRNA icon

MCF Advisors’s Moderna MRNA Stock Holding History

MCF Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$771 Buy
+11
New +$569 ﹤0.01% 1329
2026
Q1 		– Sell
-700
Closed -$20.6K – 1375
2025
Q4 		$20.6K Buy
+700
New +$19K ﹤0.01% 686
2024
Q4 		– Sell
-15
Closed -$1K – 1028
2024
Q3 		$1K Hold
15
– – ﹤0.01% 908
2024
Q2 		$1.78K Hold
15
– – ﹤0.01% 859
2024
Q1 		$1.6K Hold
15
– – ﹤0.01% 839
2023
Q4 		$1.49K Buy
+15
New +$1.26K ﹤0.01% 806
2023
Q3 		– Sell
-14
Closed -$1.7K – 938
2023
Q2 		$1.7K Hold
14
– – ﹤0.01% 727
2023
Q1 		$2.15K Hold
14
– – ﹤0.01% 700
2022
Q4 		$2.52K Buy
14
+7
+100% +$1.15K ﹤0.01% 654
2022
Q3 		$1K Sell
7
-7
-50% -$1.06K ﹤0.01% 758
2022
Q2 		$2K Buy
14
+5
+56% +$715 ﹤0.01% 635
2022
Q1 		$2K Buy
+9
New +$1.51K ﹤0.01% 648
2021
Q4 		– Sell
-12
Closed -$5K – 445
2021
Q3 		$5K Buy
+12
New +$4.43K ﹤0.01% 521
2021
Q2 		– Sell
-400
Closed -$52K – 604
2021
Q1 		$52K Hold
400
– – 0.01% 267
2020
Q4 		$42K Buy
+400
New +$40.5K 0.01% 257

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

MCF Advisors's MRNA Position: Q2 2026 in Review

MCF Advisors opened a new position in Moderna (MRNA) in Q2 2026: 11 shares worth $771. The stake represents ﹤0.01% of the portfolio and ranks #1329 among its holdings. This is a return to the name: MCF Advisors previously reported a position in MRNA as recently as Q4 2025.

MCF Advisors first reported a position in MRNA in Q4 2020 and has held it in 15 quarters since. The position peaked at $52K in Q1 2021. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • MCF Advisors held 11 shares of Moderna worth $771 as of Q2 2026.
  • Moderna was a new MCF Advisors position in Q2 2026.
  • Moderna made up ﹤0.01% of MCF Advisors's portfolio in Q2 2026, its #1329 holding.
  • MCF Advisors first reported a position in Moderna in Q4 2020 and has held it in 15 quarters since.
  • MCF Advisors's Moderna position peaked at $52K in Q1 2021.
  • 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on MCF Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.